ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
88
views
0
references
Top references
cited by
191
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,133
similar
All similar
Record
: found
Abstract
: found
Article
: found
Is Open Access
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Author(s):
Lisa Oestereich
,
Anja Lüdtke
,
Stephanie Wurr
,
Toni Rieger
,
César Muñoz-Fontela
,
Stephan Günther
Publication date
Created:
May 2014
Publication date
(Print):
May 2014
Journal:
Antiviral Research
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
PubMed
Download
XML
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is available for use in humans. Here, we evaluated the efficacy of the pyrazinecarboxamide derivative T-705 (favipiravir) against Zaire Ebola virus (EBOV) in vitro and in vivo. T-705 suppressed replication of Zaire EBOV in cell culture by 4log units with an IC90 of 110μM. Mice lacking the type I interferon receptor (IFNAR(-)(/)(-)) were used as in vivo model for Zaire EBOV-induced disease. Initiation of T-705 administration at day 6 post infection induced rapid virus clearance, reduced biochemical parameters of disease severity, and prevented a lethal outcome in 100% of the animals. The findings suggest that T-705 is a candidate for treatment of Ebola hemorrhagic fever. Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Related collections
Decoding Infection and Transmission
Author and article information
Journal
Title:
Antiviral Research
Abbreviated Title:
Antiviral Research
Publisher:
Elsevier BV
ISSN (Print):
01663542
Publication date Created:
May 2014
Publication date (Print):
May 2014
Volume
: 105
Pages
: 17-21
Article
DOI:
10.1016/j.antiviral.2014.02.014
PubMed ID:
24583123
SO-VID:
bdc22894-b109-4998-8724-4b4d50aa5696
Copyright ©
© 2014
License:
https://www.elsevier.com/tdm/userlicense/1.0/
http://creativecommons.org/licenses/by/3.0/
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,133
The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment
Authors:
Halit Cınarka
,
Gulsah Gunluoglu
,
Mustafa Çörtük
…
Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever
Authors:
Amy L. Caroline
,
Diana Powell
,
Laura M. Bethel
…
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study
Authors:
Romy Kerber
,
Eva Lorenz
,
Sophie Duraffour
…
See all similar
Cited by
182
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Authors:
Qingxian Cai
,
Minghui Yang
,
Dongjing Liu
…
Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys
Authors:
Travis Warren
,
Robert Jordan
,
Michael K Lo
…
COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities
Authors:
Melika Lotfi
,
Michael Hamblin
,
Nima Rezaei
See all cited by
Version 1
- Current
Version 1